News

The company reported a net loss of $495,000, or $0.01 per share, for the year ended December 31, 2008, compared to a net loss of $2.11 million, or

Under the terms of the contract, Aesthetic has obtained a one-year exclusive license to market the Lapex 2000 BCS series in Sweden, Norway, Denmark and Finland. Meridian signed

EnCor and SenoRx breast tissue biopsy markers have previously received regulatory clearances from China’s State Food & Drug Administration and from countries within the European Economic Community and

The new project will focus on detailed cell-based studies to further advance the validation of novel oncology target candidates successfully identified by Cenix in screens completed recently for

Dr John has most recently served as head of R&D at Centegen, a biotechnology start-up. She brings 17 years of experience in the manufacture of biologics and the

Biovitrum, a developer of protein-based medicines, and Karolinska Development, a Swedish investment company, have signed an agreement to establish a jointly owned project company. This company will receive

Sopherion Therapeutics, a developer and marketer of anticancer therapies, has completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin, or Myocet, in metastatic HER-2-overexpressing breast

Cedarburg Pharmaceuticals, a provider of active pharmaceutical ingredients and key intermediates for the pharmaceutical and biopharmaceutical industries, has acquired InB: Hauser Pharmaceutical Services, a contract development manufacturing organization.

Epix Pharmaceuticals, a biopharmaceutical company, has received a new patent from the US Patent and Trademark Office. The granted claims of this patent are directed to the highly